Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.63 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17145458 | 0.94 | SLC6A3 (0.55) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL4247382 | 0.86 | SLC6A3 (0.65) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL9154015 | 0.86 | SLC6A3 (0.65) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL11932077 | 0.85 | SLC6A3 (0.51) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL14390374 | 0.84 | SLC6A3 (0.63) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL3554782 | 0.84 | SLC6A3 (0.72) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL4206472 | 0.84 | SLC6A3 (0.65) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL4950911 | 0.83 | SLC6A3 (0.63) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL13701461 | 0.82 | SLC6A3 (0.61) | SLC6A3 | |
| SCHEMBL30902994 | 0.81 | SLC6A3 (0.62) | SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233965-A1 | Alkyl Esters Of Cyclic Amino Alcohols With Muscarinic M3 Receptor Antagonist Activity, Useful For Treating E.G. Chronic Bronchial Obstruction, Asthma And Overactive Bladder | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| US-20090233965-A1 | Alkyl Esters Of Cyclic Amino Alcohols With Muscarinic M3 Receptor Antagonist Activity, Useful For Treating E.G. Chronic Bronchial Obstruction, Asthma And Overactive Bladder | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| WO-2007123465-A1 | NEW ALKYL ESTERS OF CYCLIC AMINO ALCOHOLS WITH MUSCARINIC M3 RECEPTOR ANTAGONIST ACTIVITY, USEFUL FOR TREATING E.G. CHRONIC BRONCHIAL OBSTRUCTION, ASTHMA AND OVERACTIVE BLADDER | ASTRAZENECA AB (SE) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233965-A1 | Alkyl Esters Of Cyclic Amino Alcohols With Muscarinic M3 Receptor Antagonist Activity, Useful For Treating E.G. Chronic Bronchial Obstruction, Asthma And Overactive Bladder | CHRM3, CHRM2, CHRM1 | SLC6A3 2623/4885SLC6A2 3245/4885SLC6A4 3589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.